Stopping GLP-1 Drugs Sparks Quick Loss of Heart-Protection Benefits
A BMJ Medicine analysis of about 333,000 adults with diabetes found that consistent GLP-1 use lowers cardiovascular risk by 18% over three years, but stopping for as little as six months can raise risk by up to 8%, and pausing for one to two years can increase risk by roughly 22%, erasing the drug’s protection. Weight regain and a rebound in inflammation, blood pressure, and cholesterol accompany interruptions, which can leave a lasting “metabolic whiplash.” With many patients stopping or pausing due to cost, side effects, or shortages, the findings underscore the importance of maintaining GLP-1 therapy where possible.
